Britt Prescott is the Director of US Rare Disease at Pfizer, where they lead initiatives related to the cardiovascular and Vyndamax (tafamidis) product lines. Previously, Britt held the position of Director of US Oncology, focusing on the ORGOVYX (relugolix) launch. With experience as a Managing Consultant at Navigant, they specialized in strategy consulting for major health systems. Britt's foundational expertise was further developed through roles at Pfizer, including a Marketing Manager in the Marketing Rotational Program and a Policy Lead at Acumen LLC. They earned a Bachelor's Degree in Ecology and Evolutionary Biology from Princeton University and an MBA from Northwestern University's Kellogg School of Management.
This person is not in any teams
This person is not in any offices